Cancer and neoplasms

TERZO - A multicentre, open-label, Phase 3, randomised controlled trial of duvelisib versus investigator’s choice of gemcitabine or bendamustine in patients with relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype (SBI-0145-304) (SBI-0145-304 (TERZO))

GO TO STUDY

Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

GO TO STUDY

Cancer and neoplasms

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered In Combination With Induction And Consolidation Chemotherapy And Administered As Maintenance Therapy In Adult Patients With Newly Diagnosed Flt3-Itd Negative Acute Myeloid Leukemia (QuaNTUM-Wild)

GO TO STUDY

Oral and Gastrointestinal

Prospective non-interventional, phase IV multicentre study to assess the effectiveness, safety and tolerability of elafibranor 80 mg/day in patients with primary biliary cholangitis receiving treatment in a real-world setting. (ELfinity)

GO TO STUDY

Cancer and neoplasms

A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (BGB-11417-302 (CELESTIAL-RRMCL))

GO TO STUDY

Neurological Reproductive health and childbirth

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine

GO TO STUDY

Neurological

Interventional, randomized, double-blind, placebo-controlled, optional open-label extension trial of Lu AF82422 in participants with Multiple System Atrophy (MASCOT)

GO TO STUDY

A Prospective, Screening Study of Bleeding and Treatment in Participants with Von Willebrand Disease

GO TO STUDY

Cancer and neoplasms

A Phase 1-2 Master Protocol to Study ATTR-01 in Participants with Selected Advanced Solid Tumours (ATTEST)

GO TO STUDY

Cancer and neoplasms

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who are ineligible for, intolerant to, or have progressed on previous trastuzumab deruxtecan treatment (EmpowHER 303)

GO TO STUDY